KEYMAKER-U04 Substudy 04D: A clinical study of new treatments given with enfortumab vedotin and pembrolizumab in people with urothelial cancer (MK-3475-04D/KEYMAKER-U04)

Trial Identifier: 3475-04D
Sponsor: MSD
Start Date: February 2026
Primary Completion Date: July 2031
Study Completion Date: July 2031
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Chile, Region M. de Santiago Santiago., Region M. de Santiago, Chile, 7500921
France, Gironde Bordeaux, Gironde, France, 33075
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Netherlands, Zuid-Holland Rotterdam, Zuid-Holland, Netherlands, 3015 GD
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid Madrid, Spain, 28040
United Kingdom, London, City of London, London, City of, United Kingdom, EC1A 7BE
United States, CA San Francisco, CA, United States, 94158
United States, OH Cleveland, OH, United States, 44195
United States, UT Salt Lake City, UT, United States, 84112-5550